The American Society of Clinical Oncology (ASCO) previously published evidencebased
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …

抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> The primary objective was to
determine clinical practice guidelines for the diagnostic evaluation, treatment, and follow-up …

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy
for Stage IV Non–Small-Cell Lung Cancer | JCO Oncology Practice Skip to main content …

Lung cancer is the leading cause of cancer death in the United States in both men and
women. An estimated 226,160 new cases will be diagnosed in 2012, and 160,340 deaths …

Lung cancer is still the leading cause of cancer death worldwide, and non-small cell lung
cancer accounts for 80% to 85% of all lung cancer cases. Surgery, radiation therapy, and …

Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung
cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …